Craig-Hallum analyst Matt Hewitt assigned a Buy rating to the stock today. The company’s shares opened today at $2.06.
According to TipRanks, Hewitt is an analyst with an average return of -5.8% and a 41.63% success rate. Hewitt covers the Healthcare sector, focusing on stocks such as Apyx Medical, Codexis, and Ligand Pharma.
Apyx Medical has an analyst consensus of Moderate Buy, with a price target consensus of $3.89, an 88.83% upside from current levels. In a report released today, Lake Street also reiterated a Buy rating on the stock with a $3.00 price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $7.97 and a one-year low of $1.41. Currently, Apyx Medical has an average volume of 144.8K.
Based on the recent corporate insider activity of 6 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of APYX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Apyx Medical (APYX) Company Description:
Apyx Medical Corp. operates as an energy-based medical technology company. It engages in developing, manufacturing, and marketing a range of electrosurgical products and technologies, as well as related medical products used the offices of doctors, surgery centers, and hospitals worldwide. It operates through the following segments: Advanced Energy and Original Equipment Manufacture (OME). The company was founded by Andrew Makrides in 1978 and is headquartered in Clearwater, FL.
Read More on APYX:
